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1  | INTRODUC TION
Most cardiac structures have been demonstrated to have a relatively 
linear relationship to body size, and are commonly indexed to body 
surface area (BSA) to define abnormal values.1 Left ventricular (LV) 
wall thickness (WT) on magnetic resonance imaging has a linear rela-
tionship to BSA as noted in the Multi- Ethnic Study of Atherosclerosis,2 
but current echocardiographic guidelines recommend that increased 
WT should be defined as ≥10 mm in women and ≥11 mm in men with-
out indexing for body size.1 Identification of LV hypertrophy on echo-
cardiography carries significant prognostic implications.1,3 While LV 
mass index (LVMI) is more accurate than increased nonindexed WT 
for identification of LV hypertrophy,4 it also requires complex calcu-
lation, and previous guidelines have recognized that measurement of 
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Background: Guidelines provide normal ranges of left ventricular (LV) wall thick-
nesses (WT) without indexing. We hypothesized that indexing WT to body surface 
area (BSA) improves prognostic value.
Methods: We examined the relationship between WT and BSA in 9737 patients un-
dergoing echocardiography without risk factors for LV hypertrophy other than obe-
sity. We compared WT to BSA and examined the relationship of WT and LV mass 
index (LVMI) to mortality.
Results: There is a linear relationship between BSA and septal and posterior WT 
(r = 0.38, P < 0.001 for each). Higher quartiles of BSA were associated with increased 
WT (P < 0.001). After adjusting for age and gender, greater mean WT (MWT) (Hazards 
Ratio [HR] 1.10 per mm, 95% Confidence Interval [CI] 1.04–1.16, P = 0.001, C- statistic 
0.66), LVMI (HR 1.01, 95% CI 1.001–1.01, P = 0.01, C- statistic 0.66), and indexed 
MWT (HR 1.34 per mm/m2, 95% CI 1.23–1.47, P < 0.001, C- statistic 0.67) are each 
associated with increased mortality, with indexed MWT having the highest prognos-
tic value. Each decile of indexed MWT ≥8th decile was associated with increased 
mortality compared to the 1st decile (P < 0.01 for each). Individuals with indexed 
MWT ≥8th decile (≥5.0 mm/m2) had increased adjusted mortality (HR 1.67, 95% CI 
1.43–1.94, P < 0.001, C- statistic 0.67); this had improved prognostic value over 
guideline definitions of increased MWT (C- statistic 0.66) or LVMI (P = NS).
Conclusions: We observe a linear relationship between BSA and WT. Indexing WT 
improves mortality prediction over LVMI and nonindexed WT. These findings support 
indexing WT to BSA.
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WT may be the easiest approach to identify these patients in clinical 
practice.5 Our hypothesis was that LV WT on echocardiography has 
a linear relationship to body size, and we compared the relationship 
between WT and both BSA and height. Further, we hypothesized that 
indexed mean WT (I- MWT) would have improved prognostic value 
over nonindexed mean WT (MWT). We therefore examined the re-
lationship between WT and body size in a population without known 
cardiovascular disease undergoing echocardiography, and compared 
the prognostic significance of MWT, LVMI, and I- MWT.
2  | METHODS
We examined WT in adult patients referred for a clinically indi-
cated transthoracic echocardiogram. As recommended by recent 
guidelines for assessment of reference values with 2- dimensional 
echocardiography,1 we examined a population without known cardi-
ovascular disease and without known risk factors for increased WT 
by excluding individuals with a systolic blood pressure >140 mm Hg 
or diastolic blood pressure >80 mm Hg (mean of three values), esti-
mated glomerular filtration rate <60 mL/min/1.73 m2, or history of 
hypertension, diabetes, or hyperlipidemia. We did not exclude obese 
individuals as we specifically wanted to evaluate the relationship be-
tween LV WT and body size. We further excluded individuals with 
hypertrophic cardiomyopathy (clinical diagnosis or any WT ≥15 mm 
as per guidelines),6 myocardial infarction, or prior valve replacement. 
Finally, we excluded individuals with echocardiographic findings of 
aortic stenosis, aortic regurgitation, at least moderate mitral regur-
gitation, or a LV ejection fraction <50% (echocardiographic exclusion 
criteria). From a total population of 60 504 individuals with a com-
plete echocardiogram during 2012 through 2015, 11 483 individu-
als remained after applying clinical exclusion criteria. An additional 
1370 subjects were excluded after applying echocardiographic ex-
clusion criteria. Finally, we excluded patients with inadequate image 
quality for measurements of LV diameter and WT (n = 495); and pa-
tients without recorded BSA (n = 42). This resulted in a final cohort 
of 9737 individuals in the study. In patients with multiple studies, 
we used the first available study. The study was approved by the 
Institutional Review Board with a waiver of informed consent. The 
study is consistent with the Declaration of Helsinki.
Echocardiograms were performed at a tertiary care academic 
medical center, one of six affiliated satellite clinics located in five 
cities, and an affiliated private practice primary care hospital in a 
6th city; sites were located within three adjacent counties. All stud-
ies were performed by experienced registered cardiac sonogra-
phers and interpreted by a core group of cardiologists with Level III 
training in echocardiography within a single lab. Echocardiography 
performance followed recommended standardized guidelines 
and included comprehensive study of all cardiac structures.7 
Echocardiograms were performed using Philips EPIQ 7 and iE33 
systems (Philips Healthcare, Andover, MA); Acuson Sequoia 512 
systems (Siemens, Malvern, PA); or GE Vivid 7, Vivid 9, or Vivid E9 
systems (GE Healthcare, Wauwatosa, WI). Images were archived in 
standard DICOM format and reviewed using contemporary versions 
of Synapse Cardiovascular Client (Fujifilm Medical Systems, Valhalla, 
NY). Echocardiography measurements were performed in accor-
dance with guidelines, with WT and LV diameters performed using 
parasternal long- axis views from 2D echocardiography.1 LV mass was 
calculated using the Cube formula as recommended in guidelines.1
Clinical data were extracted from the electronic medical record. 
All- cause mortality was assessed within the electronic medical re-
cord based on its query of state and federal death records. Body sur-
face area was calculated using the Du Bois, Du Bois formula. Obesity 
was defined as body mass index ≥30 kg/m2.
Data were tested for normal distribution using the Kolmogorov–
Smirnov test. Continuous variables were compared using t tests 
and ANOVA for variables with normal distributions and the Mann–
Whitney U test and Kruskal–Wallis test for variables without a 
normal distribution. Pearson correlations were used to compare 
the linear relationship between continuous variables. To simplify 
comparisons for outcome analyses, the mean values of WT (mean 
of septal and posterior walls) were used for all analyses unless spec-
ified. Kaplan–Meier curves with the log- rank test and Cox regres-
sion analyses adjusted for age and gender were used to compare the 
relationship between WT and mortality using thresholds defined by 
guidelines and a threshold defined as elevated risk by decile of I- 
MWT. C- statistics were calculated from logistic regression models 
including age and gender. P- values <0.05 were considered signifi-
cant. Statistical analyses were performed using IBM SPSS version 24 
for Mac (IBM Corporation; Armonk, NY).
3  | RESULTS
Mean age was 49.9 ± 15.7 years, and 61.4% (5982/9737) were 
female. Mean BSA was 1.90 ± 0.26 m2, and mean height was 
1.69 ± 0.10 m. Mean body mass index was 28.0 ± 6.8 kg/m2; 30.1% 
of individuals were obese. There were 689 deaths, and mean follow-
 up was 2.4 ± 1.1 years.
There is a linear relationship (Figure 1A,B) between septal WT 
and BSA (r = 0.39 overall, r = 0.29 for women, r = 0.29 for men, 
P < 0.001 for each), and between posterior WT and BSA (r = 0.38 
overall, r = 0.29 for women, r = 0.29 for men, P < 0.001 for each). A 
statistically significant but weaker linear relationship was observed 
(Figure 1C) between septal WT and height in the overall cohort 
(r = 0.24, P < 0.001) and in men (r = 0.10 for men, P < 0.001), but 
not in women (r = 0.02, P = 0.08). Similarly, there was a linear rela-
tionship (Figure 1D) between posterior WT and height in the overall 
group (r = 0.25 overall, P < 0.001), in women (r = 0.05, P < 0.001), 
and in men (r = 0.12, P < 0.001).
Tables 1 and 2 provide median LV septal and posterior WT by 
quartile of BSA and height in the overall cohort as well as by gender, 
and demonstrate a significant increase in WT with higher quartiles 
of BSA and height. Given the higher linear relationship between WT 
and BSA as compared to height, as well as its consistency across gen-
ders, further analyses were limited to indexing WT to BSA.
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Using current guideline definitions of increased nonindexed WT 
(≥10 mm for women and ≥11 mm for men)1 in this population with-
out known risk factors other than obesity, increased WT was ob-
served with greater frequency in subjects with higher BSA quartiles 
(Figure 2).
Using the mean of the septal and posterior walls, the median in-
dexed wall thickness was 4.6 mm/m2 (interquartile range 4.1–5.1). 
There was a small difference in median indexed WT between females 
(4.6 mm/m2, interquartile range 4.2–5.2) and males (4.5 mm/m2, 
interquartile range 4.1–5.0; P < 0.001).
Increased septal WT (Hazards Ratio [HR] 1.09 per mm, 95% CI 
1.04–1.14, P < 0.001), posterior WT (HR 1.08 per mm, 95% CI 1.03–
1.13, P = 0.003), septal WT/BSA (HR 1.30 per mm/m2, 95% CI 1.20–
1.41, P < 0.001), and posterior WT/BSA (HR 1.29 per mm/m2, 95% CI 
1.19–1.41, P < 0.001) are each associated with increased mortality.
Both before and after adjusting for age and gender, greater 
MWT, LVMI, and I- MWT are each associated with increased mor-
tality, with the highest C- statistic observed with I- MWT (Table 3).
To identify a possible threshold for risk based on I- MWT, we 
examined mortality stratified by decile of I- MWT. Figure 3 demon-
strates significant differences between groups (log- rank P < 0.001). 
After adjusting for age and gender, and using the 1st decile as a 
reference, only the 8th (HR 1.12, 95% CI 1.06–1.18, P < 0.001), 9th 
(HR 1.08, 95% CI 1.03–1.13, P = 0.003), and 10th (HR 1.09, 95% CI 
1.05–1.14, P < 0.001) decile groups had increased mortality; all other 
deciles had no difference in adjusted mortality compared to the 1st 
decile (P > 0.05 for each). The ≥8th deciles of I- MWT correspond to 
a measurement of ≥5.0 mm/m2.
Table 4 demonstrates the prognostic value of MWT and LVMI 
using current guideline recommendations to define elevated values,1 
F IGURE  1 A–D, Wall thickness and body size. These figures demonstrate the linear relationship between body surface area (BSA) and 
septal WT (A), BSA and posterior WT (B), height and septal WT (C), and height and posterior WT (D). Color is used to differentiate by gender, 
and gender- specific reference lines are provided for each. WT = wall thickness
(A) (B)
(C) (D)
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TABLE  1 Left ventricular wall thickness by body surface area (BSA)
1st quartile BSA 
(<1.71 m2)
2nd quartile BSA 
(1.71–1.88 m2)
3rd quartile BSA 
(1.89–2.07 m2)
4th quartile BSA 
(>2.07 m2) P
Overall
Septal WT 8 (7–9) 8 (7–9) 9 (8–10) 10 (9–11) <0.001
Posterior WT 8 (7–9) 8 (8–9) 9 (8–10) 9 (8–10) <0.001
Women
Septal WT 8 (7–9) 8 (7–9) 9 (8–10) 9 (8–10) <0.001
Posterior WT 8 (7–9) 8 (7–9) 9 (8–9) 9 (8–10) <0.001
Men
Septal WT 8 (7–9) 9 (8–10) 9 (8–10) 10 (9–11) <0.001
Posterior WT 8 (7–9) 8 (8–10) 9 (8–10) 10 (9–11) <0.001
Median (interquartile range) provided. WT = wall thickness.
TABLE  2 Left ventricular wall thickness by height
1st quartile height 
(<1.62 m)
2nd quartile height 
(1.63–1.68 m)
3rd quartile height 
(1.68–1.77 m)
4th quartile height 
(>1.77 m) P
Overall
Septal WT 8 (7–9) 8 (7–9) 9 (8–10) 9 (8–11) <0.001
Posterior WT 8 (7–9) 8 (7–9) 9 (8–10) 9 (8–10) <0.001
Women
Septal WT 8 (7–9) 8 (7–9) 8 (7–9) 8 (8–10) 0.07
Posterior WT 8 (7–9) 8 (7–9) 8 (7–9) 9 (8–10) <0.001
Men
Septal WT 9 (8–10) 9 (8–10) 9 (8–10) 9 (8–11) <0.001
Posterior WT 9 (8–10) 9 (8–10) 9 (8–10) 9 (8–10) <0.001
Median (interquartile range) provided. WT = wall thickness.
F IGURE  2 Percentage of patients with 
increased wall thickness using current 
guidelines by quartile of body surface 
area. Increased values were defined as 
either septal or posterior WT ≥10 mm for 
women and ≥11 mm for men. *P < 0.001 
vs 1st quartile
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with the addition of I- MWT ≥5.0 mm/m2 (≥8th decile with highest 
observed risk). Of these, I- MWT has the highest prognostic value 
based on the C- statistic.
4  | DISCUSSION
In a population without known risk factors for LV hypertrophy, we 
observed a linear relationship between body size and WT, with the 
strongest relationship seen using BSA. We observed a stronger 
linear relationship between WT and BSA in comparison to height, 
and this relationship remained significant for both septal and pos-
terior walls among both genders, unlike height. These results are 
consistent with findings using cardiac magnetic resonance imaging 
in the Multi- Ethnic Study of Atherosclerosis study, which observed a 
linear relationship between WT and BSA, but not height.2
Using current guideline definitions, elevated nonindexed WT 
was common in our population without known risk factors for LV hy-
pertrophy, and became increasingly frequent among larger patients; 
this may in part be due to the high prevalence of obesity. Nearly half 
TABLE  3 Relationship between continuous measures of left ventricular hypertrophy and mortality
Unadjusted HR (95% CI) P Adjusted HR (95% CI) P C- statistic
MWT (per mm) 1.21 (1.15–1.27) <0.001 1.10 (1.04–1.16) <0.001 0.660
LVMI (per g/m2) 1.01 (1.01–1.01) <0.001 1.01 (1.001–1.01) 0.01 0.659
I- MWT (per mm/m2) 1.50 (1.38–1.62) <0.001 1.34 (1.23–1.47) <0.001 0.671
Multivariable models adjust for age and gender. I- MWT = indexed mean wall thickness; LVMI = left ventricular mass index; MWT = mean wall 
thickness.
F IGURE  3 Kaplan–Meier curve for 
mortality by decile of indexed mean wall 
thickness. Log- rank P < 0.001
TABLE  4 Relationship between presence of left ventricular hypertrophy and mortality using defined thresholds
Unadjusted HR (95% CI) P Adjusted HR (95% CI) P C- statistic
MWT ≥ 10 (females) or 11 mm 
(males)
1.60 (1.38–1.87) <0.001 1.34 (1.15–1.57) <0.001 0.662
LVMI ≥ 96 (females) or 116 g/m2 
(males)
1.46 (1.11–1.91) 0.007 1.30 (0.99–1.71) 0.06 –
I- MWT ≥ 5.0 mm/m2 1.98 (1.71–2.30) <0.001 1.67 (1.43–1.94) <0.001 0.673
Multivariable models adjust for age and gender. I- MWT = indexed mean wall thickness; LVMI = left ventricular mass index; MWT = mean wall 
thickness.
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of individuals (including the majority of women) in the top quartile of 
BSA would be classified as having increased WT, which could result 
in reporting LV hypertrophy. Calculation of LVMI could allow index-
ing to BSA, but this is not always readily available in clinical practice, 
as recognized by prior guidelines.5
An important role for imaging tests is to identify patients at in-
creased risk of adverse events. We observed that I- MWT as a con-
tinuous variable had improved prognostic performance over either 
MWT or LVMI in our population, with a higher C- statistic. It is sur-
prising that LVMI did not have superior prognostic performance, al-
though the Cube formula used to calculate it is based on geometric 
assumptions and has a potential for error.1 While I- MWT appeared 
superior to LVMI for prognostic assessment in our population, there 
is extensive evidence supporting the prognostic value of LVMI,1,3,8–10 
and further research may be warranted.
Unlike the continuous relationship that has been previously 
observed between LVMI and risk of adverse events in hyperten-
sive patients,11 we observed a different pattern in this cohort. In 
our study, individuals in the 1st through 7th deciles of I- MWT had 
no statistically significant difference in adjusted mortality using 
the 1st decile as a baseline, although increased mortality was ob-
served in the 8th and higher deciles. When we compared patients 
above vs below this threshold, the resulting multivariable model 
demonstrated higher prognostic performance than the models 
using guideline definitions of LV hypertrophy based on nonin-
dexed WT and LVMI.
Current guideline definitions of increased WT and LVMI are 
based on a threshold of 1.96 SD above the mean in a normal pop-
ulation. Our normotensive population did not have known risk fac-
tors for LV hypertrophy other than obesity12–16; however, given the 
potential for unmeasured variables and given the inclusion of obese 
individuals in our study, we instead examined the relationship be-
tween I- MWT by decile and mortality. Using this, we identified an 
outcome- based threshold of I- MWT ≥80th percentile, whereas 30% 
of individuals in our cohort would be defined as having increased 
mortality, and used this threshold to define an elevated I- MWT in 
our population. The use of this threshold to define LV hypertrophy 
had improved prognostic performance over increased nonindexed 
WT defined by current guidelines, while there was no statistically 
significant association in our population between guideline- defined 
increased LVMI and mortality.
A limitation of this study is that it examined subjects within a 
limited geographic area, although it does represent echocardio-
grams performed at eight sites in six cities. In addition, while we 
excluded individuals with known risk factors other than obesity 
for LV hypertrophy or increased WT, unmeasured variables may be 
present. We had a high rate of obese individuals, and our findings 
may not apply to other populations. Further, we examined individ-
uals referred for clinically indicated echocardiography, which may 
introduce selection bias. Nevertheless, observations of cutpoints 
associated with increased risk still may be applicable among pop-
ulations undergoing clinically indicated echocardiography. While 
studies of normal volunteers may avoid these biases,17,18 these 
studies would also be susceptible to volunteer bias, and would lack 
the statistical power of this cohort. In addition, studies were not 
blindly interpreted, which could also introduce bias. Finally, we did 
not compare our findings to other allometric models of LV mass 
or increased wall thickness,19,20 but these could be considered in 
future studies.
We observed a linear relationship between BSA and LV WT in 
a population without known risk factors for LV hypertrophy other 
than obesity. In comparison to nonindexed WT or LVMI, I- MWT 
has improved mortality prediction. These findings support indexing 
WT to BSA. Further study in other populations is needed to validate 
these findings and to establish the clinical role of indexing WT to 
define LV hypertrophy and identify patients at risk.
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